I look forward to their first ever journal publication. Have been following for 2 years and think they should concentrate on the Staph Aureus and E Coli septicaemia. There they have really no competition. The Covid-19 research is competing against maybe 500 odd competitors. I do not think the Germans will buy shares in a biotechnology company that has no scientific publications
RCE Price at posting:
$1.07 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)